JP2014506259A - Ｉｌ−２１リガンド - Google Patents

Ｉｌ−２１リガンド Download PDF

Info

Publication number
JP2014506259A
JP2014506259A JP2013548861A JP2013548861A JP2014506259A JP 2014506259 A JP2014506259 A JP 2014506259A JP 2013548861 A JP2013548861 A JP 2013548861A JP 2013548861 A JP2013548861 A JP 2013548861A JP 2014506259 A JP2014506259 A JP 2014506259A
Authority
JP
Japan
Prior art keywords
seq
hil
antibody
nnc
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013548861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506259A5 (enExample
Inventor
ラーシュ・アンデシュ・スヴェンソン
メッテ・ダール・アンデルセン
イェンス・ブラインホルト
シャーロット・ヴィーベリ
ベーリット・オールセン・クローグ
ドロテ・ルンズゴー
ハネ・ベネディクト・ラスムッセン
Original Assignee
ノヴォ ノルディスク アー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴォ ノルディスク アー／エス filed Critical ノヴォ ノルディスク アー／エス
Publication of JP2014506259A publication Critical patent/JP2014506259A/ja
Publication of JP2014506259A5 publication Critical patent/JP2014506259A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013548861A 2011-01-17 2012-01-17 Ｉｌ−２１リガンド Withdrawn JP2014506259A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP11151073 2011-01-17
EP11151073.1 2011-01-17
US201161434989P 2011-01-21 2011-01-21
US61/434,989 2011-01-21
EP11168328 2011-05-31
EP11168328.0 2011-05-31
US201161493002P 2011-06-03 2011-06-03
US61/493,002 2011-06-03
EP11187212.3 2011-10-31
EP11187212 2011-10-31
PCT/EP2012/050633 WO2012098113A1 (en) 2011-01-17 2012-01-17 Il-21 ligands

Publications (2)

Publication Number Publication Date
JP2014506259A true JP2014506259A (ja) 2014-03-13
JP2014506259A5 JP2014506259A5 (enExample) 2015-03-05

Family

ID=46515179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013548861A Withdrawn JP2014506259A (ja) 2011-01-17 2012-01-17 Ｉｌ−２１リガンド

Country Status (5)

Country Link
US (1) US20130323259A1 (enExample)
EP (1) EP2665750A1 (enExample)
JP (1) JP2014506259A (enExample)
CN (1) CN103443124A (enExample)
WO (1) WO2012098113A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1963369B1 (en) 2005-11-28 2013-05-15 Zymogenetics, Inc. Il-21 antagonists
EP2746292A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of nephropathies
EP2746293A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of cardiovascular diseases
JP2017507132A (ja) * 2014-02-07 2017-03-16 ノヴォ ノルディスク アー／エス 抗体プロセス
AR099625A1 (es) 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
JP6672175B2 (ja) * 2014-05-07 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療
SMT201900668T1 (it) 2014-06-06 2020-01-14 Bristol Myers Squibb Co Anticorpi contro il recettore per il fattore di necrosi tumorale indotto da glucocorticoidi(gitr)e loro usi
EP3304079B1 (en) 2015-06-03 2020-06-03 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
KR20180082563A (ko) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521797A (ja) * 2004-11-29 2008-06-26 ジュリアーニ インターナショナル リミテッド インターロイキン−２１の抗原性エピトープ、関連抗体及び医療分野におけるそれらの使用
JP2008148710A (ja) * 2002-12-24 2008-07-03 Rinat Neuroscience Corp 抗ｎｇｆ抗体およびそれらを使用する方法
WO2009047360A1 (en) * 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
JP2009517405A (ja) * 2005-11-28 2009-04-30 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１アンタゴニスト
JP2009520468A (ja) * 2005-12-23 2009-05-28 ヴィヴェンティア バイオテック インコーポレーティッド 融合タンパク質ライブラリーの作製法およびスクリーニング法、ならびにそれらの使用
WO2009132821A1 (en) * 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
WO2010027981A1 (en) * 2008-09-03 2010-03-11 Genentech, Inc. Multispecific antibodies
JP2010088451A (ja) * 2002-05-20 2010-04-22 Abmaxis Inc タンパク質ライブラリーのｉｎｓｉｌｉｃｏ作成と選択
WO2010055366A2 (en) * 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2010127113A2 (en) * 2009-04-29 2010-11-04 Centocor Ortho Biotech Inc. Toll-like receptor 3 antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380958T3 (es) 1999-12-23 2012-05-21 Genentech, Inc. Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010088451A (ja) * 2002-05-20 2010-04-22 Abmaxis Inc タンパク質ライブラリーのｉｎｓｉｌｉｃｏ作成と選択
JP2008148710A (ja) * 2002-12-24 2008-07-03 Rinat Neuroscience Corp 抗ｎｇｆ抗体およびそれらを使用する方法
JP2008521797A (ja) * 2004-11-29 2008-06-26 ジュリアーニ インターナショナル リミテッド インターロイキン−２１の抗原性エピトープ、関連抗体及び医療分野におけるそれらの使用
JP2009517405A (ja) * 2005-11-28 2009-04-30 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１アンタゴニスト
JP2009520468A (ja) * 2005-12-23 2009-05-28 ヴィヴェンティア バイオテック インコーポレーティッド 融合タンパク質ライブラリーの作製法およびスクリーニング法、ならびにそれらの使用
WO2009047360A1 (en) * 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
WO2010055366A2 (en) * 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2009132821A1 (en) * 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
WO2010027981A1 (en) * 2008-09-03 2010-03-11 Genentech, Inc. Multispecific antibodies
WO2010127113A2 (en) * 2009-04-29 2010-11-04 Centocor Ortho Biotech Inc. Toll-like receptor 3 antagonists

Also Published As

Publication number Publication date
EP2665750A1 (en) 2013-11-27
CN103443124A (zh) 2013-12-11
WO2012098113A1 (en) 2012-07-26
US20130323259A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
JP2014506259A (ja) Ｉｌ−２１リガンド
US11261252B2 (en) Molecules with specificity for CD79 and CD22
CN108367075B (zh) 4-1bb结合蛋白及其用途
US20190359713A1 (en) Molecules with specificity for cd45 and cd79
US11692041B2 (en) Antibody molecules which bind CD45
ES2854708T3 (es) Anticuerpos dirigidos contra la cadena alfa del receptor de IL7: su uso para la preparación de fármacos candidatos
CN112424223B (zh) 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
US10618957B2 (en) Antibody molecules which bind CD79
US11136366B2 (en) Methods of treating immune related disorders using antibody-cytokine engrafted compositions
CN106573053B (zh) 干扰素α和ω抗体拮抗剂
CN110072891A (zh) 抗人cd73抗体
TW201031421A (en) IL-1 binding proteins
CN101512008A (zh) 白介素-13结合蛋白
KR20130080058A (ko) Ｉｌ-12/ｐ40 결합 단백질
MX2012011629A (es) Proteinas de union a tnf-alfa.
CN111320693B (zh) 抗EphA4抗体
CN109071655A (zh) 具有增强的激动剂活性的cd40的抗体
CA3077304C (en) Anti-pacap antibody
CA3120804A1 (en) Btla antibodies
KR20160099083A (ko) 신규 항인간 bdca-2 항체
WO2013175427A1 (en) Il-6 binding molecules
JP2014518198A (ja) Ｉｌ−２１のエピトープおよびｉｌ−２１リガンド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171127

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180227